WHAT IS PREDICT?
PREDICT stands for Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment and is part of Vanderbilt’s Personalized Medicine program.
Personalized medicine involves tailoring treatments to a patient’s genetic profile. PREDICT aims to prospectively identify & genetically test patients who are more likely to require target medications (e.g., Clopidogrel or Warfarin) within the next 3 to 5 years. This way, genetic results will guide therapeutic decisions from initial diagnoses and drug order.
WHO IS SELECTED FOR THE PREDICT TEST?
Patients are selected based on demographic variables such as age, gender, race, and weight as well as their relevant medical history (e.g., hypertension, diabetes, coronary artery disease, dialysis, atrial fibrillation, atherosclerosis, congestive heart failure, and other conditions).
WHAT IS BEING TESTED?
DNA extracted from the patient’s blood specimen will be genotyped for 32 common single nucleotide polymorphisms (SNPs) within 8 genes associated with drug absorption, distribution, metabolism, and excretion using the QuantStudio Custom Assay PCR System. We currently test for CYP2C19, TPMT, VKORC1, CYP2C9, CYP3A5, CYP4F2, SLC01B1, and CYP2D6.
HOW WILL I RECEIVE THE RESULTS?
While 8 genes are analyzed using this technology, only those genes that have been reviewed and approved as actionable by the Vanderbilt Pharmacy & Therapeutics (P&T) committee will be made available for clinical decision support. The remaining genetic results will be stored but inaccessible within eStar (Vanderbilt’s EHR).
Depending on the results of the test, dosage adjustments for specific drugs or alternative medications may be indicated for the patient.
For management decisions regarding the clinical care of a patient, see the “Drug-Genome Interactions” section of “Patient Summary” or “Labs” in eStar. Clinical decision support may also be provided in medication prescribing tools.